FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

SANOFI-AVENTIS 		2. Issuer Name and Ticker or Trading Symbol

GENZYME CORP [ GENZ ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                      __ X __ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

174, AVENUE DE FRANCE 		3. Date of Earliest Transaction (MM/DD/YYYY)

4/6/2011
(Street)

PARIS, I0 75013
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

___ Form filed by One Reporting Person
_ X _ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock, $0.01 par value   4/6/2011     P    3947680   (1) A   (2) 187986225   I   By GC Merger Corp.   (3)
Common Stock, $0.01 par value   4/7/2011     P    44891208   (1) A   (4) 232877433   I   By GC Merger Corp.   (3)
Common Stock, $0.01 par value   4/8/2011     P    4435393   (1) A   (5) 237312826   I   By GC Merger Corp.   (3)
Common Stock, $0.01 par value   4/8/2011     P    16245894   (6) A $76.33   253558720   I   By GC Merger Corp.   (3)

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares

Explanation of Responses:
( 1)  Reflects shares purchased in an exchange offer.
( 2)  On April 6, 2011, these shares of Genzyme Corporation ("Genzyme") common stock were exchanged for cash and a contingent value right (each, a "CVR") pursuant to GC Merger Corp.'s ("Purchaser") offer to exchange each issued and outstanding share of Genzyme common stock for $74.00 in cash and one CVR. The closing price of Genzyme common stock on April 5, 2011 was $76.33.
( 3)  The shares are held by Purchaser. The Purchaser is a direct, wholly-owned subsidiary of sanofi-aventis ("Parent"). The shares may also be deemed to be indirectly beneficially owned by Parent.
( 4)  On April 7, 2011, these shares of Genzyme common stock were exchanged for cash and one CVR pursuant to Purchaser's offer to exchange each issued and outstanding share of Genzyme common stock for $74.00 in cash and one CVR. The closing price of Genzyme common stock on April 6, 2011 was 76.38.
( 5)  On April 8, 2011, these shares of Genzyme common stock were exchanged for cash and one CVR pursuant to Purchaser's offer to exchange each issued and outstanding share of Genzyme common stock for $74.00 in cash and one CVR. The closing price of Genzyme common stock on April 7, 2011 was 76.33.
( 6)  Reflects shares acquired by Purchaser pursuant to the exercise of the "top-up" option provided for in the Agreement and Plan of Merger, dated as of February 16, 2011 among Parent, Purchaser and Genzyme.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
SANOFI-AVENTIS
174, AVENUE DE FRANCE
PARIS, I0 75013
X

GC Merger Corp.
55 CORPORATE DRIVE
BRIDGEWATER, NJ 08807
X


Signatures
/s/ SEE EXHIBIT 99.1 4/8/2011
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Genzyme (NASDAQ:GENZ)
과거 데이터 주식 차트
부터 12월(12) 2024 으로 1월(1) 2025 Genzyme 차트를 더 보려면 여기를 클릭.
Genzyme (NASDAQ:GENZ)
과거 데이터 주식 차트
부터 1월(1) 2024 으로 1월(1) 2025 Genzyme 차트를 더 보려면 여기를 클릭.